Algernon Pharmaceuticals Announces Closing of Private Placement
August 20, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Increase to Private Placement
August 13, 2024 07:18 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Private Placement
August 07, 2024 17:02 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Closing of Private Placement
August 02, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Pharmaceuticals Announces Increase to Private Placement
July 31, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
July 16, 2024 08:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Private Placement
July 11, 2024 16:15 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
May 21, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
April 24, 2024 07:47 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
April 11, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite...